NY-PHILIP-MORRIS-INTL
21.9.2021 22:26:05 CEST | Business Wire | Press release
Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (PMI) (NYSE: PM), today delivered remarks at the 2021 Concordia Annual Summit . Olczak discussed the need to draw on the lessons learned from the global response to COVID-19 and create transparent frameworks and partnerships that harness innovation to build a better world. He explained the importance of focusing on peer-reviewed science to tackle major global issues—including environmental pressure, social inequality, health pandemic, and smoking. Olczak described how the exclusionary practices of many anti-tobacco organizations and NGOs are making it harder for PMI to deliver tobacco harm reduction solutions by introducing scientifically substantiated alternatives as the company moves away from making and selling cigarettes.
The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.
Excerpts of Jacek Olczak’s speech follow.
“We have come together today to talk about resilience and recovery. To share our insights and ideas for how to build a world that is better for all.
“Two things are certain: We cannot build the future we desire by relying on the same blueprints we used to construct our recent past. And returning to a version of yesterday’s ‘normal’ is unthinkable. It would be a dereliction of duty and an unforgivable waste of the opportunity before us to evolve and grow as a society.
“With COVID-19, we have been handed a terrible burden … and a gift. An opportunity to create our world anew, drawing on the lessons we have learned during 18 months of lockdowns and fear and uncertainty.
“A lesson that has been especially resonant for me is just how irrational it is to attempt to address a massive global challenge—such as the current pandemic—from behind closed doors and without input from all concerned parties. Moreover, our recent experiences have shown me how counterproductive it is to prioritize certain people and perspectives over all others to the point of obscuring truths and blocking innovative and more immediate solutions.
“We have an opportunity to build a better world, but we cannot do that until we open the doors to new partnerships and new frameworks. To initiate change, we need to open our minds and be willing to welcome all pertinent parties and perspectives to the table. To recover, rebuild, and repair our world, we must act in unison as a global community rather than be led by provincial thinking.
“As the CEO of Philip Morris International, I have witnessed how the ‘old normal’ ways of working are heaving roadblocks along the path to progress.
“The situation we face as a company is relatively simple: Globally, more than 1 billion people continue to smoke cigarettes. We can all agree that this is a bad thing—for those individuals and for the public health. Regulatory measures to reduce that number have had limited effect, but not nearly enough to solve the problem. The answers for the future lie squarely in a fierce commitment to science and technological innovation.
“Over the past decade, we have had an enormous scientific and technological breakthrough: Companies such as mine have developed smoke-free products that eliminate combustion—products such as e-cigarettes and heated tobacco systems. While not risk-free, these products have been scientifically substantiated to be a much better alternative to continued smoking.
“That’s great news, isn’t it? Adults who continue to smoke now have better alternatives to cigarettes. Who could oppose them switching to these better options?
“You would be surprised.
“Rather than celebrate what by any objective measure is a positive public health breakthrough, some special interest groups are prioritizing ideology, politics, and a desire for retribution over progress. Fixated on the fantasy of an entirely tobacco-free world, they have lost sight of the opportunity that exists today, refusing to accept the science behind these alternatives and rejecting harm reduction as a solution for better.
“We need only look at Japan to see a market in which the introduction of heated tobacco products directly correlates to an accelerated decline in cigarette use.
“Equally troubling, authorities worldwide are being influenced by lavishly funded special interest groups and NGOs afraid to lose the funding they gain from continuing to fight a last-century battle. Constructs put in place through the WHO’s Framework Convention on Tobacco Control are willfully being misinterpreted. For example, Article 5.3 of the Convention, intended to limit industry influence—something we respect and support—is wielded to censor and ostracize critics, silence reasoned voices, and stymie debate.
“The closed doors, secrecy, and intrigue that marked criticism of the tobacco industry 30 years ago are now, ironically, standard practice for many anti-tobacco organizations and NGOs. Unfortunately, their tactics are making it harder for my company to achieve our goal of no longer making or selling cigarettes. As we expand our business for the long term outside of tobacco and nicotine and invest in pharma, we are faced with the same illogical exclusion.
“The misplaced fear and resistance to change must be addressed.
“We need to remove politics and ideological principles that are impeding progress—and not only with regard to tobacco harm reduction. The harms of exclusionary policies and counterproductive measures apply with similar force to climate change, pandemic mitigation, institutionalized inequity, and other pressing challenges.
“Intentionally or not, the ‘old guard’ has created a world that is failing the majority. They have championed policies that prioritize the status quo rather than embracing intelligent change.
“It is time for new voices. It is time for more inclusive and pragmatic approaches.
“Science—when vetted through peer review—is science. Facts are facts. The notion that a scientific finding must be flawed because it comes from a particular company or industry is absurd—especially when it has been confirmed by respected governments, scientists, and other third parties. We need to remove the stigma that scientific innovation funded by a tobacco company cannot possibly be reliable or in the public interest. Equally essential, we need to stop excluding men and women who smoke from the conversation. These are the people who have the most to gain from reduced-risk alternatives. They must be allowed a voice.
“We can continue to allow these groups to prescribe who gets to be engaged in solving problems—even when they have precious little to show for their decades of work. Or we can instead work together—as smartly and as quickly as possible—to tackle the very real issues that threaten us all.
“It is human nature to stick with what we know. Thanks to the great pause of COVID-19, we have had time to reflect on where that tendency has gotten us. What we need now is not more of the same but fresh thinking. We need to break out of our echo chambers and monolithic committees and conferences so that innovative thinking and science can get through. Healthy debate requires differences and dissent. I would urge those of you gathered here today to ask how we can create a better tomorrow. Will it be by doubling down on dogma and division, or will it be by embracing collaboration, diversity, and inclusivity? The challenges before us are mighty. The consequences of our failing to meet them are great.
“I am not here to ratchet up tensions. Quite the opposite. I am here to ask you to help put a stop to outdated, exclusionary approaches that are preventing us from moving forward as a society. And I am asking you to put the public health over ideology and ancient grudges. If we have learned one thing this past year and a half, it is that science, innovation, and inclusion must be permitted to prevail.
“I stand before you four months into my role as CEO of PMI, a company undergoing a profound transformation.
We are passionate in our commitment to unsmoke the world and create a better future—a future free of cigarettes. Now, we need you—and all those in positions of influence—to join us in unsmoking minds so we can rebuild a better future for all, faster.”
A recording of the speech will be available to view at www.pmi.com/unsmokethefuture
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2021, PMI’s smoke-free products are available for sale in 67 markets in key cities or nationwide, and PMI estimates that approximately 14.7 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921006085/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
